US Federal Court Rules that Perrigo Does Not Infringe Mucinex’ Patents

Perrigo has obtained a valuable US Federal Court ruling that its generic version of Mucinex, a drug made by Reckitt Benckiser subsidiary Adams Respiratory Therapeutics, does not infringe on Adams’ patent.

The drug, a decongestant, is used to treat various respiratory conditions including asthma and bronchial infections.

Perrigo is now waiting for final U.S. Food and Drug Administration approval for the drug.

As the first company to successfully challenge the claim that patent term extension for Mucinex’s patent to 2020, Perrigo is entitiled to six months marketing exclusivity for generic version.



Categories: Israel, News, Patents, pharmaceuticals, pharmaceuticals and Biotechnology, US

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: